3B BlackBio Dx Limited reported a consolidated net profit of ₹5992.98 lakh for the financial year ended March 31, 2026, an increase of 25.7% from ₹4769.11 lakh in the previous year. Revenue from operations for the year rose 47.1% to ₹14191.81 lakh from ₹9646.86 lakh in FY25. The Board of Directors recommended a final dividend of ₹5.00 per equity share, subject to shareholder approval at the ensuing Annual General Meeting. The company's Molecular Diagnostics (MDx) division closed the year with revenue of ₹13111.81 lakh, while the Agro-Chemical division recorded export sales of ₹277.74 lakh.

Quarterly Performance

For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹980.48 lakh, compared to ₹803.55 lakh in the corresponding quarter of the previous year. Revenue from operations for Q4 stood at ₹3543.41 lakh. On a standalone basis, Q4 net profit came in at ₹744.65 lakh versus ₹924.39 lakh in the same quarter of the previous year, while Q4 standalone revenue stood at ₹2463.01 lakh compared to ₹2301.97 lakh year-on-year.

The company's Q4 EBITDA improved to ₹1464.62 lakh from ₹1253.91 lakh year-on-year. The following table summarises the key quarterly metrics:

Consolidated Financial Results (FY26)

The standalone net profit for the full year was ₹4931.69 lakh, while revenue from operations was ₹9727.50 lakh. The Board, in its meeting held on May 29, 2026, approved the audited standalone and consolidated financial results. Baheti & Company, Statutory Auditors, issued an unmodified opinion on the financial results. The Board also appointed M/s Ali Jain & Sharma, Chartered Accountants, as the Internal Auditor for the financial year 2026-27.

The full-year consolidated financial highlights are presented below:

Segment Performance and Outlook

The Molecular Diagnostics division, contributing the majority of sales, reported revenue of ₹13111.81 lakh for FY26. The division holds approximately 15% market share in the Indian Molecular Diagnostics market, estimated at ₹500–600 Cr. The company expects the MDx industry to grow at 8%–10% CAGR and targets a growth of 15%–20% for FY 2026–27.

The Agro-Chemical division maintained focus on government procurement and exports. Export sales for the division amounted to ₹277.74 lakh in 2025-26 compared to ₹356.75 lakh in 2024-25, a de-growth of 22% attributed to geopolitical tensions in Bangladesh. The division operates with minimal debt and focuses on supplying to existing customers and government tenders.

Notable Developments

Other expenses for the year included one-time fees of ₹174.08 lakh for M&A advisory and due diligence related to the acquisition of Coris Bioconcept SRL, Belgium. The decline in other income was attributed to lower net asset values of debt mutual funds consequent to moderation in interest rates. The company has successfully passed its IVDR-aligned QMS audits conducted by BSI Group in November 2025, with technical evaluation of product groups underway.

3b blackbio dx Limited has formally declared to BSE Limited that it does not qualify as a Large Corporate under the Securities and Exchange Board of India (SEBI) regulatory framework, thereby exempting itself from specific disclosure requirements.

Updated Regulatory Compliance Declaration

The company submitted its latest declaration on April 15, 2026, addressing the non-applicability of disclosure requirements outlined in SEBI circular SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023. The formal communication was directed to the Department of Corporate Relations at BSE Limited.

Corporate Authorization

The declaration was duly authorized and digitally signed by key company officials. Company Secretary Navneet Kaur (ACS No. 29130) and Chief Financial Officer Nikhil Kuber Dubey (DIN: 00538049) both provided their digital signatures on April 15, 2026, at 16:14:22 and 16:15:03 respectively.

SEBI Large Corporate Framework

The SEBI circular dated October 19, 2023, establishes specific criteria for categorizing companies as Large Corporates, which triggers additional disclosure obligations. By confirming its non-applicability under these criteria, 3B BlackBio Dx Limited has clarified its regulatory status and compliance obligations to the stock exchange.

The company's formal submission serves as an official record with BSE Limited, ensuring transparency regarding its regulatory classification and associated disclosure requirements under current SEBI guidelines.